Solasia Pharma K.K. provided consolidated earnings guidance for the fiscal year ending December 31, 2023. For the year, the company expects revenue in the range of ¥1,000 million to ¥1,800 million, operating loss in the range of ¥1,150 million to ¥350 million, loss in the range of ¥1,150 million to ¥350 million, basic loss per share in the range of ¥6.85 to ¥2.08.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
28 JPY | +3.70% | +3.70% | -37.78% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-37.78% | 31.47M | |
-2.47% | 89.37B | |
+2.76% | 40.65B | |
-12.44% | 32.81B | |
+52.41% | 25B | |
-17.27% | 15.29B | |
-42.45% | 11.61B | |
-10.48% | 11.49B | |
+6.14% | 8.98B | |
-7.72% | 8.23B |
- Stock Market
- Equities
- 4597 Stock
- News Solasia Pharma K.K.
- Solasia Pharma K.K. Provides Consolidated Earnings Guidance for the Fiscal Year Ending December 31, 2023